{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:38:52Z","timestamp":1761917932529,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.metabol.2022.155397","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T19:53:55Z","timestamp":1672343635000},"page":"155397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos E.","family":"Rodopaios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhanu","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155397_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.exger.2012.11.004","article-title":"Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells","volume":"48","author":"Bowser","year":"2013","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.metabol.2022.155397_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1196\/annals.1315.023","article-title":"Activins and inhibins and their signaling","volume":"1038","author":"Vale","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.metabol.2022.155397_bb0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467211205020195","article-title":"Activin receptor signaling: a potential therapeutic target for osteoporosis","volume":"5","author":"Lotinun","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.metabol.2022.155397_bb0020","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00198-012-2198-0","article-title":"Circulating activin-a is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment","volume":"24","author":"Anastasilakis","year":"2013","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.metabol.2022.155397_bb0025","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.1152\/ajpendo.00193.2009","article-title":"Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin","volume":"297","author":"Gilson","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155397_bb0030","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.metabol.2016.07.002","article-title":"Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans","volume":"65","author":"Anastasilakis","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155397_bb0035","article-title":"Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-beta signaling pathway","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2022.155397_bb0040","first-page":"38","article-title":"Follistatin effects in migration, vascularization, and osteogenesis in vitro and bone repair in vivo","volume":"7","author":"Fahmy-Garcia","year":"2019","journal-title":"Front BioengBiotechnol"},{"key":"10.1016\/j.metabol.2022.155397_bb0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/endo.143.1.8580","article-title":"Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures","volume":"143","author":"Gaddy-Kurten","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2022.155397_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11914-008-0009-5","article-title":"Inhibin and the regulation of bone mass","volume":"6","author":"Gaddy","year":"2008","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.metabol.2022.155397_bb0055","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/jc.2005-2423","article-title":"Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone","volume":"91","author":"Perrien","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155397_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.maturitas.2005.01.009","article-title":"Ovarian aging and bone metabolism in menstruating women aged 35\u201350 years","volume":"52","author":"Vural","year":"2005","journal-title":"Maturitas"},{"key":"10.1016\/j.metabol.2022.155397_bb0065","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1096\/fj.201801969RR","article-title":"A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice","volume":"33","author":"Lodberg","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2022.155397_bb0070","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1073\/pnas.1916034117","article-title":"GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN\/GDF11 inhibitor, increases muscle mass but weakens bone","volume":"117","author":"Suh","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2022.155397_bb0075","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/jc.2011-1665","article-title":"Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin a and follistatin but not myostatin in healthy males","volume":"96","author":"Vamvini","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155397_bb0080","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1210\/jc.2011-1453","article-title":"Short-term energy deprivation alters activin a and follistatin but not inhibin B levels of lean healthy women in a leptin-independent manner","volume":"96","author":"Moragianni","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155397_bb0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.metabol.2018.05.003","article-title":"Regulation of the activins-follistatins-inhibins axis by energy status: impact on reproductive function","volume":"85","author":"Perakakis","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155397_bb0090","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1152\/ajpendo.00146.2011","article-title":"Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women","volume":"301","author":"Brinkoetter","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155397_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154392","article-title":"Circulating profile of activin-follistatin-inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment","volume":"113","author":"Bouzoni","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155397_bb0100","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.metabol.2016.03.005","article-title":"Ciliary neurotrophic factor upregulates follistatin and Pak1, causes overexpression of muscle differentiation related genes and downregulation of established atrophy mediators in skeletal muscle","volume":"65","author":"Tsompanidis","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155397_bb0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.metabol.2011.05.016","article-title":"Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women","volume":"60","author":"Sienkiewicz","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155397_bb0110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4000418","article-title":"Leptin in relation to resumption of menses in women with anorexia nervosa","volume":"3","author":"Audi","year":"1998","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.metabol.2022.155397_bb0115","doi-asserted-by":"crossref","first-page":"2469S","DOI":"10.1093\/jn\/134.9.2469S","article-title":"The role of leptin in regulating neuroendocrine function in humans","volume":"134","author":"Bluher","year":"2004","journal-title":"J Nutr"},{"key":"10.1016\/j.metabol.2022.155397_bb0120","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-a signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2022.155397_bb0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bone.2018.02.026","article-title":"A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia","volume":"110","author":"Lodberg","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2022.155397_bb0130","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in cynomolgus monkeys","volume":"46","author":"Lotinun","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2022.155397_bb0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bone.2009.09.018","article-title":"Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis)","volume":"46","author":"Fajardo","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2022.155397_bb0140","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952200275X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952200275X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:29:57Z","timestamp":1758428997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952200275X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"alternative-id":["S002604952200275X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155397","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155397"}}